Katholieke Universiteit Leuven

Janssen Pharmaceutica Nv

Katholieke Universiteit Leuven, Ku Leuven R&d

Mohamed Koukni

Arnaud Marchand

Johan Neyts

Kai Dallmeier

Dorothée Bardiot

Wim Smets

Suzanne Kaptein

Gunter Carlens

Michael McNaughton

Andrés Avelino Trabanco-Suárez

José Maria Cid-Núñez

Francisco Javier Fernández-Gadea

Georges Joseph Cornelius Hoornaert

Frans Josef Cornelius Compernolle

Tomasz Kozlecki

Hua Mao

Sushil Chandra Jha

Antonius Adrianus Hendrikus Petrus Megens

Antonius Andrianus Hendrikus Petrus Megens

Dorothee Bardiot

Michael Mcnaughton

The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

Viral replication inhibitors

The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds. 

This invention concerns novel substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives with binding affinities towards serotonin receptors, in particular 5-HTand 5-HTreceptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim

Substituted tetracyclic tetahydrofuran, pyrrolidine and tetrahydrothiophene derivatives

Growing community of inventors

Leuven, Belgium

Mohamed Koukni